HK Stock Market Move | HENLIUS (02696) rose more than 4%, Hanlicon received approval for two new indications, and 7 innovative pipelines will be unveiled at the AACR conference.

HENLIUS (02696) rose more than 4%, as of the time of writing, it increased by 4.44% to HK$83.55, with a turnover of HK$87.7622 million. On the news front, on April 9th, HENLIUS announced that the supplementary application for two new indications for Hanlikang (rituximab) developed and produced independently by the company for non-Hodgkin's lymphoma has been approved by the National Medical Products Administration (NMPA). As China's first biosimilar drug, Hanlikang has fully covered all indications approved for the original rituximab on the market in China, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis not approved in China, becoming the rituximab with the most approved indications in China. It is worth noting that the American Association for Cancer Research Annual Meeting (AACR 2026) will be held in San Diego, USA from April 17th to 22nd, 2026. At this year's AACR conference, HENLIUS will focus on several new ADCs (HLX43 PD-L1 ADC, HLX316 B7-H3sialic acid hydrolase fusion protein, HLX3902 STEAP1CD3CD28 tri-specific TCE) developed based on its own platforms such as Hanjugator, showcasing seven early-stage innovative assets with "first-in-class" or "best-in-class" potential, including EGFRxcMET bispecific ADC HLX48, HER2 bisite ADC HLX49, ADAM9 ADC HLX402, ALPP/ALPPL2 ADC HLX85.